{"name":"Mirum Pharmaceuticals, Inc.","slug":"mirum-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":19138000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-23363000,"cash":296683000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Livmarli Oral Product","genericName":"Livmarli Oral Product","slug":"livmarli-oral-product","indication":"Other","status":"marketed"},{"name":"High dose of MRM-3379","genericName":"High dose of MRM-3379","slug":"high-dose-of-mrm-3379","indication":"Other","status":"phase_2"},{"name":"Livmarli","genericName":"Livmarli","slug":"livmarli","indication":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CDCA Weight-Based Dose TID","genericName":"CDCA Weight-Based Dose TID","slug":"cdca-weight-based-dose-tid","indication":"Progressive familial intrahepatic cholestasis (PFIC) type 1","status":"phase_3"},{"name":"Cholic Acids","genericName":"Cholic Acids","slug":"cholic-acids","indication":"Cerebrotendinous xanthomatosis (CTX)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Cholbam","genericName":"Cholbam","slug":"cholbam","indication":"3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency","status":"marketed"}]}],"pipeline":[{"name":"CDCA Weight-Based Dose TID","genericName":"CDCA Weight-Based Dose TID","slug":"cdca-weight-based-dose-tid","phase":"phase_3","mechanism":"CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis.","indications":["Progressive familial intrahepatic cholestasis (PFIC) type 1","Progressive familial intrahepatic cholestasis (PFIC) type 2"],"catalyst":""},{"name":"Livmarli Oral Product","genericName":"Livmarli Oral Product","slug":"livmarli-oral-product","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cholbam","genericName":"Cholbam","slug":"cholbam","phase":"marketed","mechanism":"G-protein coupled bile acid receptor 1, Bile acid receptor","indications":["3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency","Calculus in biliary tract","Cholestanol storage disease","Constipation","Delta-4-3-oxosteroid-5-beta-reductase deficiency"],"catalyst":""},{"name":"Cholic Acids","genericName":"Cholic Acids","slug":"cholic-acids","phase":"phase_3","mechanism":"Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders.","indications":["Cerebrotendinous xanthomatosis (CTX)","Progressive familial intrahepatic cholestasis (PFIC)","Bile acid synthesis disorders"],"catalyst":""},{"name":"High dose of MRM-3379","genericName":"High dose of MRM-3379","slug":"high-dose-of-mrm-3379","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Livmarli","genericName":"Livmarli","slug":"livmarli","phase":"marketed","mechanism":"Ileal sodium/bile acid cotransporter","indications":["Cholestatic pruritus in patients with Alagille syndrome (ALGS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeEY1aEZ1WGxwdU9HWVRKZHJtT2xFVlpiYjIzMkJ5RWNyWXBEdVMyU01GYmRXcTNoWHNmNEk2NDlHY3NFWjB3dFIwSEdUQ2ctZG9tUVZMU29hOG8yTXdoZzhYOWw1enRsaHoyaEo5S1FjTDZyWGdLa285X2w0RnQ4dlRUODVzR1JKNzlKdFRtUDJyTUFVeXJLTlR4OWVHWWNkelg4OHhVemRuQU9aRUlpZ3pJclZUbjQ0RjM1Tkxpbms?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"New Mirum hires get stock options at $91.75 in latest grants - Stock Titan","headline":"New Mirum hires get stock options at $91.75 in latest grants","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQeDVmOVFiblhUSHBYV25JU1F5bGtyeTEwb0VFUzltUE1RMnRUaUJhLVE2NDFGcERaa2JQQUJ1RUhmTFZrcUtHSW9Fem1ZQS1oVmpfSmVZYUhYRmZfTk9wYmgtUXFaNXdzNFlsTWZ1UFFjWjR6UVZ5RXFkZm1ncGtfekNudDdsT0VQZWt0SWNzTDNUbDVnak10OGFmWDlwdEdZR05CWXdNTDNSSXEtc21OSV9ObjFBRmJZTjJxZTQ0LV9NS2Nh?oc=5","date":"2026-02-23","type":"pipeline","source":"Business Wire","summary":"Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire","headline":"Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQZC1mWFgxOTZrT2N6d1RrMFBKT25fU1MyQ2tmWmVTbXRLQVM1ZXNnMlZObEd6WkphaGtkTWpyUkFKakp4Z2Y5Snp1WHloaFBPZXpfZzJOVmNzUU1CbWtoUEhfOEdXdS1WUWI2UmU1cmRqTzltMmxnNXZWYWUxRDIzS29PUEhrOTc3TlBMUlV0bU1idUFMSk4xOUxUZ3A3Y0wyMWtuRG1NZE1Uc0p6N1JoTDNEaFg2MXU0U2doTUVB?oc=5","date":"2026-02-18","type":"pipeline","source":"Stock Titan","summary":"Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan","headline":"Drugmaker Mirum sets Feb. 25 call on 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQMWs3c3dqcGZZTEFCNDBzX3JCaDZDZzFlTWpPQVZMU2RCQ0Vic2hIeTFnNUZTRWd6emJGZS1lWDVJS25IX2hINFp0QzQxWGNNUVg2VkhERTRCYmRhRks1UEsydUphT1UzOU01c3FTeHVZUFVJUmxTR1ROVFNaSTA3eXZn?oc=5","date":"2026-02-03","type":"pipeline","source":"Pharma Voice","summary":"Mirum doubles down on diversified rare disease strategy - Pharma Voice","headline":"Mirum doubles down on diversified rare disease strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNLWtpdThxLWgwdDZhUXl5S1BPbXlERU9jc1psaFZYT05qcVpzX1FaQThrS2x3SmtCLXJiV0R5dGVLeVRkMlhBTW9VcDl5ZVZFcWZFVkZoNlo0dkVHR24zUnVZSkZMT3F2RzhyZGxFXy03d2l4UEx2akdJQnlSZHd0aTJ2Z0p1VUV2LXFtTFQ3ZTdoTkRPS0tYS0U5LXZQTmdQV1ZKTXpXclRjWTl3MWtZT2wxamxvN3VaX0RCYWtUNkpFNmhBZ1lHSGtPWGR1VEZRQ2VaUEZBSUx6bkd5X3hjMWVURk9sYjF3WFo0TURqU3VEZ1FaRG9BX0ZFNmQ?oc=5","date":"2026-01-26","type":"pipeline","source":"Business Wire","summary":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire","headline":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOc0k1SGZKTzBEWVgzZlEtQnFIdVZoY3lTQ1JiSHJsVWNuNmk3TjRJUnVCVnpwR0F2RjQxWS1sWlBPZzNab2prb0ZOaERsVGs0VG1vUEJhdmplMzl0dEZzR21zXzV2cXdsR2IxYk43RnFLeF85b2VZY1YyQzI0d0xPMw?oc=5","date":"2026-01-20","type":"deal","source":"Yahoo Finance","summary":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - Yahoo Finance","headline":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxONjdlME8tbXhPRHJ2T2Vaa3E5RVJaU2piRXhUV3dRX0ZleGk2aUpRanBWdzNJLUZUSlNpTjh2cjRJZWNuLUNWSklSaDZOVndiSml4c25YTVlNSUFUeDBFeThhOTlUb0VSUFVvM3RaRXg3N2p4dGJyd3E2V1lNQ25VRHlNTTRmaWVfQ0d3ZFNTMDFfU1pmSjIwNWVXVmZvY0pjdkw1ejljNFNTQnRpcVpHRDRSUVVXazlxaHZYMkcyV0ZsSnNhbEk0aUhldU4zMXIzNENN?oc=5","date":"2025-12-19","type":"pipeline","source":"Business Wire","summary":"Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Business Wire","headline":"Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNNFVmV2J0VVdGNENRYnF4TmRMU0YxYWNpMjhGLXpxZ2pidGR5OFBXcUI0Q0ZUNVRYMjNmSzl4LU1lbHh2NHByQTlLZHVnTWRzUXlyQzNnakh0ZDhQV2VRUWdhOW1wWFlld2dMUDJGTV9Nbi1XVmhIN0hoNHVjdEFCLTNlN0dhYXBKNzRUMzQ1M1RVVTFOQm9meE9zVHZMcmF3NGZyZVRpT09aWlg4T3ZPMGpiTUNGaFZLSk5TRXZ1YkNRQmVYdklDVHZ5Z2IwZVFZMmZv?oc=5","date":"2025-12-10","type":"pipeline","source":"Business Wire","summary":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire","headline":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdnVsZXJacllkXzE5aDUwU3p2ZmRvN0lURGdBTWV2QXRyaVB6dEZOSHBuSjRwd2s4V2EyRHR2UkZwUU9RRS1lWlJhemc0R05TaGwxNFpmaXNpYWoxaGpyREY2VExHZkU0M0dOVWxUWE1QZ1kxVS1yNkp3WWlYa0VOTXJfc0FSdlR2RGxfZXZZeGVCLU5mOHp4bWJNbW9HNEFRc2s0Sk96VkY?oc=5","date":"2025-12-08","type":"deal","source":"Reuters","summary":"Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - Reuters","headline":"Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOX0hVRlBUa0diREFxeVY5dXloQjVGUy1TNTVkSW1QeUtfRWw2U3otRVhGUE9mV0hEaXhKQ0ZDWUFac1l1SmtYRnprR0paME82czE4cDRjSXQ4Q2xvRl9QOC1iRl9FNE5wSDMxMkptSVFOQ1haMDRVUGEzX2JBN2ZmbU5Rc3NqRTgzZml3amx3N1h6NlhhZU1EVVllN0ZWR3ZZV1BIRTR3RGQ0SWhOSHBja3BkSWdtN2lnUERwSXV5OXFkS2sxWlFLazZnelhaRkRFRzZCU3Frc2dqSEJ0ZzhYTEVCMWEyZktZcGE2dFdMYXhmWVZKZmFVcmVhNEhMTnY3Y3VMbkVxbV95d1lVeGVEakxrMmlvdw?oc=5","date":"2025-12-08","type":"deal","source":"Business Wire","summary":"Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire","headline":"Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOOERTSC1WUjZQUWZDUTc4QWdMOVpDSzlVMVJfdXFEYUpNMmVGbFNZeW5fdXBodEdTa2tGMDVxRlpIRFdIcTM0VDBweHEtM0hRa0JOLXhDTEJDUmNzZW8wUTRoNUhrVmtGaG1lWWgwXzNBSWpuODNWVExEMW5mUjBKblE3NlRQLTRhU2hXLWdMZnYySFdQMGpiRVFpdzZoN2M0bG1Ic3FKMFFkVFdIRjBKeXNpN0ktWEwtZ0wxZ2s0OEo?oc=5","date":"2025-02-21","type":"regulatory","source":"Reuters","summary":"US FDA approves Mirum Pharma's genetic disorder drug - Reuters","headline":"US FDA approves Mirum Pharma's genetic disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTC1ENWhGX3pNbGJrUHRIN1lEZ1Zqd1ZHdmViNkdBOTQxZUNzSXo0RmhSVlcwWkdSLV9zWHFlNEZOY2NmbnBkQ0lYZ1YzYUpJMFFvMjFPYTd2MUZ4X2lwUVg2SUFFUWsxcE50RlMwTE9mV25EMzRPczdXVWdaTlFMZUZwTGE2WDVvY2xudkdMUWx1OHFqSEhBci1JcHZOUVlJV3NyZ3kwOWJfSjc0a040?oc=5","date":"2025-01-08","type":"deal","source":"Seeking Alpha","summary":"Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha","headline":"Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM)","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":2,"marketed":3,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":19138000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":19138000,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-23363000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":296683000,"cashHistory":[],"totalAssets":842813000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}